4//SEC Filing
SALIX PHARMACEUTICALS LTD 4
Accession 0001209191-14-054519
CIK 0001009356operating
Filed
Aug 25, 8:00 PM ET
Accepted
Aug 26, 6:49 PM ET
Size
9.9 KB
Accession
0001209191-14-054519
Insider Transaction Report
Form 4
D ALONZO THOMAS
Director
Transactions
- Award
Common Stock
2014-08-22$158.30/sh+3,185$504,186→ 80,925 total
Holdings
- 10,450(indirect: By Trust)
Common Stock
- 6,500(indirect: By Spouse)
Common Stock
- 1,080(indirect: By Trust)
Common Stock
- 260(indirect: By LP)
Common Stock
- 15,000
Option to Buy Common Stock
Exercise: $17.63Exp: 2015-06-09→ Common Stock (15,000 underlying)
Footnotes (4)
- [F1]In connection with the transaction contemplated by the Agreement and Plan of Merger, dated as of July 8, 2014, by and among Salix Pharmaceuticals, Ltd. ("Salix"), Cosmo Pharmaceuticals S.p.A., Cosmo Technologies Limited and Sangiovese, LLC (the "Transaction"), the Board of Directors of Salix approved special grants (the "Special Grants") of restricted stock to directors and eligible employees, including Thomas W. D'Alonzo (the "Reporting Person"), intended to lessen the potential tax burden that would be triggered upon the completion of the Transaction. The reported transaction specified in this Form 4 consists solely of the shares of restricted stock granted to the Reporting Person pursuant to the Special Grants.
- [F2]The shares are held by the Thomas W. D'Alonzo Rev Trust U/A DTD 10/24/2001 for which the Reporting Person serves as co-trustee.
- [F3]The shares are held by the Rachel L. D'Alonzo Rev Trust U/A DTD 10/24/2001 for which the Reporting Person serves as co-trustee.
- [F4]Options are 100% vested.
Documents
Issuer
SALIX PHARMACEUTICALS LTD
CIK 0001009356
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001009356
Filing Metadata
- Form type
- 4
- Filed
- Aug 25, 8:00 PM ET
- Accepted
- Aug 26, 6:49 PM ET
- Size
- 9.9 KB